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Abstract
Perimenopause is a mandatory period in women’s life, when the medical staff may initiate
hormone therapy with sex steroids for the delay of brain aging and neurodegenerative
diseases, during the so-called “window of opportunity.” Animals’ models are helpful to
sustain the still controversial results of human clinical observational and/or randomized
controlled studies. Estrogens, progesterone, and androgens, with their nuclear and mem-
brane receptors, genes, and epigenetics, with their connections to cholinergic, GABAergic,
serotoninergic, and glutamatergic systems are involved in women’s normal brain or in
brain’s pathology. The sex steroids are active through direct and/or indirect mechanisms to
modulate and/or to protect brain plasticity, and vessels network, fuel metabolism—glucose,
ketones, ATP, to reduce insulin resistance, and inflammation of the aging brain through
blood-brain barrier disruption, microglial aberrant activation, and neural cell survival/loss.
Keywords: perimenopause, “window” of opportunity, neuroprotection, sex steroid
hormones
1. Introduction
The months/years of perimenopause represent an important moment during women’s aging,
when sex steroids and their receptors decline are evident in the hippocampal and cortical neu-
rons, after estrogen exposure during the reproductive years. The sex steroid hormones decline is
associated/acts synergic to other factors as hypertension, diabetes, hypoxia/obstructive sleep
apnea, obesity, vitamin B12/folate deficiency, depression, and traumatic brain injury to promote
diverse pathological mechanisms involved in brain aging, memory impairment, and AD.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Sex steroid hormones involvement in aging brain. The perimenopausal
“window” of opportunity for neuroprotection
Perimenopause represents the critical period during women’s brain aging when it is possible
to use the “window” of opportunity to delay/postpone the proved deleterious effects of sex
steroids decline. The complex/complicated feedback loops between non-reproductive brain
regions—prefrontal neocortex, hippocampus, amigdala, and brainstem, thalamus and hypo-
thalamus, and the ovaries are made by sex steroid hormones, their network receptors through
the entire brain, enzymes involved in their metabolism, their metabolites, neurotransmitters,
cytokines, chemokines, and many other proteins/peptides. A multitude of studies are demon-
strating the effects of estrogens (estradiol-E2, estetrol-E4, and in a less measure estrone-E1),
progesterone, and androgens in brain during reproductive years, and have preventive func-
tions to cognitive and memory performances, being involved in brain bioenergetic control by
regulation of glucose transport, aerobic glycolysis coupled to the citric acid cycle, and mito-
chondrial respiration to generate ATP [1], and also in anti-inflammatory actions in the biology
of neuroaging and neurodegenerative diseases. These effects of sex steroids are covering the
two hypothesis of neurodegeneration discussed in the previous chapter.
Beside involvement in reproduction, sex steroids exert regulatory actions on the receptors in
non-reproductive brain regions, including (but not limited to) prefrontal cortex and hippocam-
pus, amigdala, thalamus, and brainstem, which occur via neural circuitry linking the hypothal-
amus to other CNS systems.
The steroid hormones are acting by indirect mechanisms on coagulation, metabolisms to prevent
atherosclerosis, and to vasodilation of cerebral vessels, increasing the blood flow to the hippo-
campus and left superior temporal gyrus [2], and through direct cellular mechanisms on differ-
ent types of neurons, microglia, and astroglia, on their synapses particularly in the brain regions
that show preclinical abnormalities in individuals who are at risk for AD (Table 1).
Starting from basic science, preclinical and clinical studies, experimental, observational, and
controlled trials are linked to estrogen-inducible neuroprotective, neurotrophic, and neuro-
genic actions. There are animal (rats, mice, non-human primates) and human evidences on
cellular mechanisms of estrogen-regulated functions/systems, which are presented in Table 2.
2.1. Estrogens’ involvement in brain aging
All types of studies have demonstrated that the neuroprotective effects of estrogens—mainly
17 β—and 17α-estradiol, progesterone, and androgens (DHEA mainly) are on the vessels,
neurons, microglia, and astroglia. The vast majority of gynecological, endocrinological, and/
or neurological research studies are about the thrombotic and ischemic stroke risks after the
age of 50 years (median age of menopause).
Observational studies on large numbers of cases from North America as the Baltimore Longi-
tudinal Study of Aging [3], the Manhattan Study of Aging [4] have associated HT/ET to
significant prevention or delay onset of AD, or reduction risk of AD (9/156 [5.8%] estrogen
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users vs. 158/968 [16.3%] nonusers; 0.40 [95% Cl 0.22–0.85], p < 0.01), and for a longer duration
than 1 year, with no effect observed for the age of menopause. At that moment, the researchers
considered the necessity of prospective studies for the establishment of the dose and duration
of ET to provide this benefit and to assess the safety in elderly postmenopausal women.
The “healthy-cell bias” hypothesis demonstrated the E2 neural different effects at different
ages, and at different stages of Aβ presence, making the explanations of different results
Author(s)/year Type of
study
Steroid Action/Effect
Tang et al. [138] Prospective
observational
(1–5 yrs.
follow-up)
E2 Estrogen promotes the growth and survival of cholinergic
neurons, and could decrease cerebral Aβ deposition, both of
which may delay the onset or prevent AD.
Maki and
Resnick [2]
Prospective
(2 yrs.
follow-up)
E2 Increasing the blood flow to the hippocampus and left superior
temporal gyrus
McEwen et al.
[79]
Adams et al.
[37]
Experimental
Experimental
E2
E2
Estrogen synapses formation in the CA1 region of the dorsal
hippocampus during the estrous cycle of the female rat
E2 did not induced the increased synapses number in aged rats
Zhang et al.,
[34]
Experimental 17β E2, testosterone or
methyl-testosterone
Estrogen & Androgen Protection of Human Neurons against
Intracellular Amyloid Toxicity through Heat Shock Protein 70
Xu et al. [139] Basic study E2 Provides protection against β-amyloid-induced damage and
tau-related changes
Norbury et al.
[140]
RCT E2 Maintenance of the cholinergic system in the hippocampus and
frontal cortex
Persad et al.
[141]
RCT Ethinyl-E2 and
progestin
Increased activation in brain regions associated with the left
middle/superior frontal cortex, and left inferior parietal cortex
during verbal memory encoding tasks on functional magnetic
resonance imaging
Harburger
et al. [64]
Experimental E2 + progesterone E2 alone and combined E2 + P4 may influence ERK activation
in different time frames or enhance memory of objects
recognition in young ovariectomized mice
Silverman et al.
[142]
RCT E2 Higher metabolism in language processing and auditory
association areas compared to other HRT regimens (CEE or
CEE + MPA)
Yao et al. [143] Experimental 17β-E2 Early correction of bioenergetics deficits, and mitochondrial
β-amyloid deposition when ovarian hormones decline
Zhao et al. [52] Experimental E2 + CyP4
vs.
E2 + CoP4
Differential regulation of hippocampal gene expression
according to P4 supplementation to E2
Tskitishvili
et al. [46]
Experimental E4 Antioxidative actions,
neurogenesis and possibly promyelinating activities
Legend: E2: estradiol; Ethinyl-E2: ethinylestradiol; MPA: medroxyprogesterone acetate; CEE: conjugated equine estro-
gens; RCT: randomized control trial; CyP4: progesterone cylic; CoP4: progesterone continuous
Table 1. Actions/effects of sex steroid hormones on brain aging.
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between experimental, observational studies and large RCT, that E2 is beneficial on rats’ healthy
hippocampal neurons before Aβ exposure [4–6]. More than this hypothesis on “healthy-cell
bias,” there are discussions and comments about the discrepancies between basic science and/or
observational studies supporting estrogen neuroprotective effects and RCT results, focusing the
attention to age, stage of reproductive aging, duration of hypogonadism, and the presence of
symptoms of cognition or memory impairment, in the efforts for reconciliations [7] between HT
and risk for AD [17]. If neurons are healthy at the time of estrogen exposure, their response to
estrogen is beneficial for both neuronal survival and neurological function. In contrast, if neuro-
logical health is compromised, estrogen exposure over time exacerbates neurological demise.
These last two statements represent the opinion of Brinton [8] from the Department of Pharma-
cology and Pharmaceutical Sciences of California University (USA). In concordance to these
facts, the North American and Chinese researchers had elaborated, and tried to confirm the
“hypothesis of critical period of estrogen neuroprotection,” which appreciates the risk of dura-
tion of estrogen deprivation [9]. It was suggested as a “critical period” or a “critical window of
opportunity” for the beneficial protective effect of E2 on the human brain [10, 11], and that
estrogens have to be administered at perimenopause or earlier to observe a beneficial effect on
the neural system [12, 13], as it is for the cardiovascular system.
A consensus began to emerge (although not without controversies) that HT/ET at the time of
the menopause transition and afterward could have beneficial effects on several neurological
Estrogen-regulated functions/systems Reference(s)
• Estrogens prevent apoptotic death cascades and neuronal death Lebesgue et al. [40]
Etgen et al. [144]
Inagaki et al. [42];
Etgen and Inagaki
[41]
• Estradiol rapidly stimulates signaling cascades: as the mitogen-activated protein (MAP)
kinase family and the phosphatidylinositol 3-kinase (PI3K), pathway leading to the phos-
phorylation of Akt (a key signaling molecule), and Akt can promote local protein synthesis
related to the formation of new spines through a non-genomic mechanism
• Estradiol increases phosphorylated Akt (pAkt) present in CA1 dendrites, spines, and syn-
apses
Cordey et al. [145]
Znamensky et al. [90]
Zhao et al. [146];
Mannella and
Brinton [86];
• Estrogens increase the dendritic spine and synaptic density by 30% on CA1 pyramidal cells
in the hippocampus
• Estrogens provide potential to protect or have the capacity to alter synaptic and postsynap-
tic circuitry in hypothalamus, hippocampus, and neocortex
Gould et al. [36];
Adams et al. [147]
Choi et al. [148].
• Estrogen- induced mitochondrial functions in brain bioenergetics
• Estradiol promotes mitochondrial respiration and hence ATP generation and antioxidant
enzymes that offset the increase in free radical generation induced by increased respiration
• Estradiol significantly reduces mitochondrial lipid peroxidation
Nilsen and Brinton
[149].
Nilsen et al. [150].
Simpkins et al. [151]
• Estrogen-induced calcium signaling pathways both promote neuronal function and can
exacerbate neuronal demise in neurodegenerative disease states.
Brewer et al. [152]
• Estrogens augment the glutamatergic impact on hippocampal function Zhao et al. [153];
• Estrogens exerts on the GABAergic and cholinergic systems in the hippocampus and frontal
cortex
Rudick et al. [154]
Tinkler et al. [155].
Table 2. Evidences on cellular mechanisms of estrogen-regulated functions/systems.
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symptoms [7, 14]. The actions of sex steroid hormones are bidirectional to the body periphery
and to the brain, and today, there are current evidences that estrogen and progesterone may
have beneficial, neutral, or detrimental effects on the brain, depending on age at therapy
initiation, type of menopause (natural vs. induced), or stage of menopause, specificity of
administered medication, mainly the association of E2 to progesterone (P4) (exogenous), active
on cognition through its 5α-reduced metabolite, allopregnanolone [15].
There are characteristics that contribute to several discrepancies in the results: age, stage of
reproductive aging, duration of hypogonadism, and symptoms presence. A better understand-
ing of the nature of these discrepancies will be base for future studies of clinical relevance of
ovarian steroids and hormone therapies in women.
The Canadian gynecologists [16] were the first who described neurological and psychological
disturbances after oophorectomy, than the Italian gynecologists [17]. One may consider that
these surgical circumstances are an abrupt, deep decline/withdrawal of steroids, different from
the gradual decline in natural menopause, and the cognitive decline in surgical/chemical
menopause is more severe [18]. In natural menopause, either premature or early or at the
median age of 51 years, the hormonal decline is on a slow slope for E2 and E1, and the
androgens (testosterone, androstenedione, and dehydroepiandrosterone) [19] are still present
up to the age of 65 [20].
Professional organizations including the British Menopause Society [21], the International
Menopause Society [22], and North American Menopause Society [23] recommend estrogen
replacement therapy for women with premature menopause or premature ovarian failure.
There are evidences, although not from RCT that restoring pathologically low estrogen
levels will reduce the later development of cardiovascular disease, osteoporosis, and possi-
bly dementia. This leads to the general recommendation that estrogen be continued in
women who experience premature menopause or early menopause until at least around the
median age of natural menopause (approximate age 51 years), effects which are evident up
to 60 years for women in natural menopause treated for menopausal symptoms [10]. Differ-
ent to this category of age, the initiation of ET alone or in combination with a progestin in the
late postmenopausal stage (ages 65–79 years) induced an increased risk of dementia and
cognitive decline regardless of the type of menopause ([10], citing WHIMS), as the “contin-
uum of neurological health progresses from healthy to unhealthy so to do the benefits of ET/
HT” [4].
2.1.1. Animal models
Experimental evidences support the favorable estrogen effect in neurons, on spinogenesis and
synaptogenesis, and the rationale option for the prevention/reduction of the risk or the delay of
the onset of AD in postmenopausal women. The North American experiments of McEwen at
the Laboratory of Neuroendocrinology from The Rockefeller University, New York, on rats’
brain in the years of 1990s’ were a surprising discovery on the modulation of hippocampal
structural plasticity done by estrogens, and it was considered as a “whole new field in the
science” [24]. In the animal models, there are differences between species, regarding reproduc-
tive and brain aging scenarios, both changes precede natural reproductive failure [7]. There are
some similarities between humans and rodents, and differences between rats and mice.
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Estrogens influence the process of adult neurogenesis. E2 promotes the migration of newly
generated neurons toward the damaged brain regions, facilitating brain remodeling, and
repair after ischemic stroke injury [25].
E2 induces neuronal plasticity underlying cognitive function. Acute E2 treatment promotes
hippocampal neurogenesis in the female rat [26], which has been linked to hippocampal-
dependent learning and memory [27]. It was revealed on rats experiments [28] that different
forms of estrogens modulate neuroplasticity and cognition in complex and intriguing ways.
Estrogens specifically up-regulate adult hippocampal neurogenesis (via cell proliferation) and
synaptic protein levels in the hippocampus in a time- and dose-dependent manner [29]. Low
levels of E2 facilitate spatial working memory and contextual fear conditioning, while high
levels of estradiol impair spatial working, spatial reference memory and contextual fear condi-
tioning, and estrone (E1) impairs contextual fear conditioning. The rats’ experiments show that
only 17β-E2 and not E1 is increasing the survival and activation of new neurons in the
hippocampus in response to spatial memory compared to controls [30].
The Chinese experiments on menopausal mice had identified morphological changes in the
hippocampus mitochondrial damage, lipofuscin deposition and microtubule degradation,
which were possible to be partially restored: mitochondrial damage and lipofuscin increase,
not the microtubules degradation, and only in early postmenopausal stages [31].
Regarding the first hypothesis on bioenergetics failure in females’ brain aging, animal models
demonstrated estrogens effects on mitochondria energetic metabolism. E2 is regulating mito-
chondrial proteome, being a key metabolic control of enzymes including pyruvate dehydroge-
nase, aconitase, and ATP-synthetase, and so it is a high respiratory control ratio, elevated
cytochrome-c oxidase activity and expression, and it is reduced brain free radical generation
[32], according to the knowledge that in aging brain is a high lactate level [30].
E2 is able to mitigate negative effects of glucocorticoids, as animal and human researches
indicate: E2-related mitigation of glucocorticoid damage and interference is one benefit of E2
supplementation during perimenopause or soon after menopause. The evidence for E2-related
protection against glucocorticoids suggests that maintaining E2 levels in postmenopausal
women could protect them from stress-induced declines in neural and cognitive integrity [33].
Physiological doses of 17β-E2, testosterone or methyl-testosterone reduce induced cell death
by 50% in neurons treated after the injection and by 80–90% in neurons treated 1 h before the
injection [34]. The effect is mediated by genomic mechanisms proved by the blockage of ERs
and ARs, and by a proteomic mechanism—the increasing levels of heat shock protein 70
(Hsp70), and the hormones role is to protect from the development and toxicity of the intracel-
lular Aβ (iA1–42), which induces neuronal apoptosis and death, being known that AD starts
with intraneuronal iA1–42 accumulation in human brain [35].
The “estrogen action hypothesis” known as “healthy-cell bias” elaborated in the North American
Laboratories for Neuroscience Research [4, 5, 8] tries to explain the differences between the
effects of estrogens on normal/healthy neurons and aged/damaged neurons. It was demon-
strated with different doses (low dose of 10 ng/ml and large dose of 200 ng/ml) and on different
schedules (acute vs. continuous vs. intermittent) in experiments on rats’ hippocampal neurons
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exposed to Aβ, that is possible to prevent neurodegeneration when E2 is administered before or
during Aβ exposure, the strongest effect being on continuous administration, and the effects are
worsened up to neuronal death when are large doses or when Aβ is already present. These
results were obtained after previous studies regarding estrogen critical different effects on syn-
aptic system at different rats’ ages. Whereas, young rats displayed a 30% increase in axospinous
synapse density in CA1 [36], fact which is absent in aged rats [37], as is mentioned in Table 2.
There are findings in rodents and monkeys providing evidences that the hippocampus (in rats)
and the frontal cortex (in monkeys) remain responsive to E2 administered either in vivo or
in vitro even after prolonged periods of hormone withdrawal [38, 39]. The physiological
concentrations of E2 exert profound neuroprotective action on apoptotic death cascades and
neuronal death from focal and global ischemia causing selective, delayed death of hippocam-
pal CA1 neurons and associated cognitive deficits after a single injection in acute ischemia [40].
E2 administered at physiological levels for 2 weeks before ischemia rescues neurons destined
to die in the hippocampal CA1, and ameliorates ischemia-induced cognitive deficits in ovari-
ectomized female rats [41]. An acute post-ischemic infusion of E2 into the brain ventricles is
neuroprotective in aged rats after 6 months of hormone deprivation, and E2 enhances synaptic
transmission in CA1 pyramidal neurons of aged long-term hormone deprived females [42].
There are evidences about distinct estrogens effects on different cognitive aspects, anxiety-like,
and depressive-like behaviors. There are comparisons regarding the subregion-specific effects
on tryptophan hydroxylase-2 (TpH2, the brain-specific, rate-limiting enzyme for 5-HT biosyn-
thesis, a serotonin precursor). The comparison of CEE and E2 treatments on behavior and
TpH2 mRNA on female ovariectomized Sprague Dawley rats [43]. Both CEE and E2 exert
beneficial behavioral effects, although efficacy depended on the distinct behavior and for
cognition, on the task difficulty. Compared to CEE, E2 generally had more robust anxiolytic
and antidepressant effects. E2 increased TpH2 mRNA in the caudal and mid dorsal raphe
nucleus. The recent Chinese study on adult male Sprague Dawley rats [44] demonstrated that
low dose E2 administered for the first 3-months after bilateral common carotid artery occlu-
sion (BCCAO) exerted long-lasting beneficial effects, including significant neuroprotection of
hippocampal CA1 neurons and preservation of hippocampal-dependent cognitive function
when examined at 6 months after BCCAO.
Recent evidences demonstrate a de novo estradiol synthesis within the hippocampus and other
brain regions, which seems highly likely that activity-dependent estradiol signaling can play
an essential role in the modulation of discrete signaling units within individual cells, affording
“fine- tuned” control of neuronal excitability [45].
Animals and in vitro studies are demonstrating the role of estetrol (E4) on nervous system. The
antioxidative actions of E4 mostly depend on ER-α and ER-β, whereas neurogenesis and
possibly promyelinating activities might be realized through ER-β, and the membrane GRP30
receptor for estrogens and progesterone is less important for LDH activity and cell survival in
E4 actions [46].
The animal experiments reconcile the discordance between studies showing favorable ste-
roids/estrogen effects in neurons to the results from former randomized trials, as the largest
randomized clinical trial of HT ever conducted—Women’s Health Initiative Memory Study
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(WHIMS), which showed that women who initiated estrogen therapy alone or in combination
with the progestin MPA after the age of 60 years had a twofold greater risk to develop dementia
[47] or are affected regarding mean cognitive performance over periods of time ranging up to
5 years [10], or estrogen-containing hormone therapy initiated in the late postmenopausal stage
(ages 65–79 years) is followed by an increased risk of dementia and cognitive decline regardless
the type of menopause—naturally, medically, or surgically induced [48].
2.1.2. Human studies
The Mayo Clinic Cohort Studies of Oophorectomy and Aging—unilateral or bilateral oopho-
rectomy [48–50] and estrogens, before the age of menopause. The risk of cognitive impairment/
dementia is increased after either unilateral or bilateral oophorectomy compared to referent
women (Hazard ratio [HR] of 1.46; 95% CI 1.13 to 1.90; adjusted for education, type of
interview, and history of depression). These associations were similar regardless of oophorec-
tomy indication, and for women who underwent unilateral or bilateral oophorectomy were
considered separately. The risk increased with younger age at oophorectomy (test for linear
trend; adjusted p < 0.0001). The same study group from the Mayo Clinic showed that women
who underwent bilateral oophorectomy before menopause were at increased risk of Parkin-
sonism, and the risk increased with younger age at time of oophorectomy [49, 50]. Their
conclusion was a sizeable neuroprotective effect of estrogen before the age of 50 years.
Some studies are sustaining that estrogen neuroprotective actions are modulated by progester-
one/progestogens. Specifically, continuous progestogen exposure is associated with inhibition of
estrogen actions, whereas cyclic delivery of progestogens may enhance neural benefits of estro-
gen [51]. In the next subchapter, more evidences on these findings are discussed. The North
American study [52] provides evidence at the molecular level that different regimens of HT can
induce disparate gene expression profiles in brain. From a translational perspective, confirma-
tion of these results in a model of natural menopause would imply that the common regimen of
continuous combined HT may have adverse consequences, whereas a cyclic combined regimen,
which is more physiological, could be an effective strategy to maintain neurological health and
function. It has to be remembered that different factors may determine the efficacy of ER/HT as
age, menopausal status, route of administration and dose, the starting cognitive function, and
the presence of pre-existing risk factors (smoking, apolipoprotein E genotype) [53].
2.2. Progesterone neuroprotective role in women’s aging
During menopausal transition on assists at lowering progesterone (P4) values by luteal defect,
and afterward in perimenopause P4 which is absent, and at the beginning of the history of HT
recommendations, P4 administration was mandatory for women with intact uterus, fact that
continues to be actual. There were intensive efforts to develop progesterone neurobiology in the
hippocampus and cortex, and current discoveries are sustaining P4 administration for more than
uterine protection from endometrial hyperplasia and cancer, but for brain aging protection,
besides the much analyzed “therapeutic window” of progesterone in brain trauma. P4 is active
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on cognition through its 5α-reduced metabolite, allopregnanolone [15, 54], a fact that differenti-
ates P4 from the progestin MPA, which proved as a jeopardizing drug for elder postmenopausal
women. P4 has neuroprotective effects mediated by various mechanisms such as reduction of
neuronal vulnerability to neurotoxic molecules, reduction of cell loss, inhibition of lipid peroxi-
dation, and expression of pro-inflammatory genes [55–57]. P4 can exert protective effects
through its metabolites—allopregnanolone or 3α, 5α-tetrahydroprogesterone, the best known,
which can interact with membrane-associated receptors coupled to ion-channels, such as the
GABAA receptor system. P4 and allopregnanolone, exert various effects on both cognitive and
non-mnemonic functions in females. Allopregnanolone may also elicit its protective effects
through its actions on the mitochondria [58]. Allopregnanolone is enhancing cognitive perfor-
mances and placement memory in mice, by inducing higher levels of brain-derived neurotrophic
factor (BDNF) in the prefrontal cortex and hippocampus, an effect that is contrary to the lowest
levels amongmice administeredMPA [15]. MPA—the progestin used to balance CEE inWHIMS
—was proved by in vitro studies to be the best antagonist to neurotrophic and neuroprotective
estrogen actions in neurons, fact that makes it completely different to P4 which alone is
neuroprotective [59], and acts synergistic with estradiol [60]. MPA (Provera®) metabolic involve-
ment is also divergent from P4, regarding the action on nuclear mitogen-activated protein kinase
signaling [61], and on the exacerbation of neuroexcitotoxicity of glutamate [62]. The well-known
object recognition task is a valuable experimental paradigm that can be used to determine the
effects and mechanisms of progestogens for mnemonic effects across the lifespan. Improvements
in object recognition performance of rodents are often associated with higher hormone levels in
the hippocampus and prefrontal cortex during natural cycles, with progesterone replacement
following ovariectomy in young animals, or with aging [54].
The estrogens neuroprotective actions are modulated by progesterone. It was demonstrated [63] in
young ovariectomized mice that E2 enhances object memory consolidation, which depends on
dorsal hippocampal activation of the extracellular signal-regulated kinase/mitogen-activated pro-
tein kinase (ERK/MAPK) signaling pathway, and the questions were if the E2 actions need proges-
terone adding, which was latter demonstrated, and more than this the effect is E2 dose-dependent
[64]. It was suggested that E2 alone, and combined with P4, may influence ERK activation in
different time frames or enhance memory through different mechanisms. E2 alone significantly
increased phospho-p42 ERK protein levels in the dorsal hippocampus relative to vehicle controls.
In contrast, no combination of E2 and P4 affected dorsal hippocampal phospho-ERK levels.
2.3. Androgens neuroprotective role in women’s aging
Recent studies on normal age-related testosterone and its androgen metabolite dihydrotestos-
terone (DHT) loss in plasma and brain in men are emerging AD risk, and the protective role of
endogenous testosterone/DHT is not only to increase the neuronal resilience against AD-
related insults, but also to reduce intracellular Aβ accumulation [34, 36, 52], testosterone
actions are similar, but also cumulative to those of estrogens in perimenopausal women. In
perimenopause, estrogens and androgens are still in physiological levels in plasma and brain,
and their presence is considered to prevent the accumulation of intracellular amyloid 1-42
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(iA1-42) in the hippocampus and the entorhinal cortex neurons, preceding amyloid plaque
formation, and further induction of neuronal death [65]. Proteomic analyses are demonstrating
increased levels of Hsp70 in testosterone- and estrogen-treated human neurons [15], which is a
sign of Aβ toxicity inhibition.
Cell cultures are bringing strong evidences that both androgens and estrogens are neuroprotective,
and many studies analyzed the different pathways for neural cells protection from Aβ toxicity.
Testosterone is involved in regulation of spine synapse density in the CA1 region of hippocampus
[66].
A special analysis is to be made on DHEA(S)—the “youth” hormone—for which human body
does not have receptors, but it is a source of intracrinology, with different enzymes for steroid-
forming and/or for steroid-inactivating, permitting each cell/tissue to synthesize a small
amount of androgens and/or estrogens in order to meet the local physiological needs without
affecting the other tissues of the organism [67]. Blood concentrations are not different from
those observed in normal postmenopausal women having high serum DHEA concentrations,
when DHES is supplemented to maintain serum estrogen level at sub-threshold or biologically
inactive concentrations.
On the other hand, all androgens are made intracellularly from DHEA by the mechanisms of
intracrinology, and are always maintained at very low levels in the blood in pre- and postmen-
opausal women [67]. According to this conceptus, it was proposed a short-term DHEA supple-
mentation (5 mg/day 7 days) in perimenopausal female rhesusmacaques [68]. The comparison
of serum and hippocampal levels in treated and controls of the same age revealed that despite
lower concentrations of the estrogens in the serum of elder animals, their concentrations in the
hippocampus did not show any obvious differences due to age or to DHEA supplementation.
The results suggest that de novo estrogen synthesis in the brain may compensate for the perimen-
opausal loss of estrogens in the circulation even without supplemental DHEA.
3. Receptors mediators of sex steroid hormone signaling
mechanisms of action in neuroprotection
The sex steroids can protect through the activation of transcriptional activity in the genomic
mechanism or via signaling of neurons survival pathways [69–71] or via non-genomic mecha-
nism through membrane receptors.
More and more studies/trials are presenting new insights of sex steroids involvement in
hypothalamic, hippocampal, and other brain neurons, their actions being partially common
to other organs/tissues effects, but with important peculiarities. The well-known mediation via
intracellular receptor/transcription factors that interact with steroid response elements on
target genes, regarding the genomic mechanism, is doubled or tripled in the speed of alter-
ations of the neuronal activity within seconds, indicating that some cellular effects can occur
via membrane delimited events. Sex steroid hormone ligands bind to membrane-associated G
protein-coupled receptor (GPR 30) [72], and caveolin proteins have an essential role for
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membrane receptors [73]. In addition, estrogens can affect metabotropic glutamate receptors,
and the second messenger systems, including calcium mobilization, and a plethora of kinases
to alter cell signaling. This subchapter considers the current knowledge of rapid membrane-
initiated and intracellular signaling by steroids in the brain, the nature of receptors involved,
and how they contribute to homeostatic functions.
3.1. Estrogen receptors (ERs). Genetic polymorphism and epigenetics of ERs
The protective role of estrogens in the brain is sure, and the missing preventive effects revealed
by RCT is connected to the age-related changes of ERs, as it is in the endometrium/uterus [74],
suggesting that several key players in the local synaptic response to E2 are compromised in
aging females. The brain has one of the most complex and complicated ERs network of the
body, which is changing life-long. In addition to its well-documented hormonal action, E2 is
considered as a neurotransmitter in the brain [75].
In the last 10 years, molecular and biochemical animal studies are demonstrating that the
mechanisms used by estrogens are greatly influenced by brain cell type, ER type, and
metabotropic glutamate receptors (mGluRs) independent of glutamate, and/or region of
the brain-cortex and/or hippocampus, all these leading to differential regulation of neuro-
nal circuitry in each area [45, 76]. The hippocampus cognitive performance is directly
connected to ER-α, other ERs such as ER-β and GPR30 [8]. The ERs have similar distribu-
tion in female and male brains, but may differ in relative expression [77]. ER-α and ER-β
expression patterns generally overlap, where ER-α is associated with reproductive behav-
ior, whereas ER-β is associated with non-reproductive behaviors such as learning and
memory [78] and anxiety-related behaviors. In hippocampus and cortical neurons, the
estrogens—mainly E2 and other estrogenic ligands bind to membrane—associated and
mitochondrial-associated G protein-coupled receptor (GPR 30), and activates the classical/
canonical nuclear and extranuclear or intra-cytoplasmatic ER isoforms—α and β—function-
ing as transcription factors [79–81], and a new type of nuclear ER, the orphan estrogen-
related receptor γ (ERR γ), which regulates dopaminergic neuronal phenotype [82], and
IGF-1 receptor, which was recently recognized as a receptor for estrogens.
The nongenomic or alternative signaling pathways mechanism involving extranuclear ERs
respond to physiological concentration of estrogens to elicit neuroprotection, resulting in the
“fine tuning” of neuronal circuitry [45]. Often, rapid activation of intracellular signalers such
as mitogen-activated protein kinase (MAPK) or phosphatidylinositol-3-kinase (PI3K) underlie
alternative estrogen-induced neuroprotection upon activation of specific binding sites at the
plasma membrane. The plasma membrane ER (mER) originates from, or is related to canonical
nuclear ERs, and GPR30 mimics short latency E2 facilitation of synaptic transmission in the
hippocampus, to enhance memory and cognition [83]. The activation of GPR30 by G-1 (its
specific ligand) is associated with a mobilization of calcium in dissociated and cultured rat
hypothalamic neurons [80, 84, 85]. There were elaborated cellular models of Aβ toxicity where
classical and alternative pathways activated by estrogens seem to coexist to orchestrate
neuroprotection, fact that is a unique signaling profile of estrogen neuroprotection, dependent
upon activation of the MAPK signaling [86].
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ER-α and ER-βmediate the effects of E2 on both intracellular signaling and gene transcription,
sharing similar domain organization, and using almost identical DNA-binding elements, co-
regulators, and transcription machinery. There are differences between ER-labeled regarding
each female, species (rats, non-human primates, human), age (young, old), estrogen levels,
brain reference area, vulnerability of spines/synapses based on size (large or small), or presyn-
aptic/postsynaptic location of ER. Both, ER-α and ER-β are located predominantly at extranu-
clear sites; ER-α are found in dendritic spines, many originating from pyramidal cells, axons,
terminals, astrocytes, and microglia [81], in symmetric and asymmetric synapses. ER-β is
detected on or near the plasma membrane of somata and dendritic shafts and spines in
hippocampal neurons [81], in axons and axon terminals and both in the cytoplasm and on
endomembranes near mitochondria in vivo [81], and within mitochondria in vitro, in pyramidal
cells, in newly generated cells in a few interneurons and in glia [81]. Changes in ER-β expres-
sion occur in the presynaptic membrane, cleft, and postsynaptic membranes, where neuro-
transmitter release and postsynaptic receptor binding occurs. Conversely, ER-α changes are
detected presynaptically in synaptic vesicles and postsynaptically in plasmalemmal and cyto-
plasmic regions of spine heads where protein translation occurs. In aged animals, it was
demonstrated for the first time [78] that the window for E2-mediated benefits on cognition
and hippocampal E2 responsiveness can be reinstated by increased expression of ER-α.
Studies have determined that membrane-localized ER-α and ER-β are capable of activating
multiple metabotropic glutamate receptors (mGluRs) independent of glutamate, leading to
downstream second messenger signaling [73, 76]. The expression of ER-α and ER-β mRNA in
the hippocampus is limited [87], and GPR30 may be the major receptor subtype by which
estrogen produces its enhancing effects. The physiological consequence of activation of GPR30
can regulate local synthesis pathways in a novel direction of our understanding of rapid
estrogen signaling within the brain and its ability to induce the “fine-tuning” of neuronal
circuits [45]. E2 works as a neuroprotector by membrane receptors coupled to E2 induction of
intracellular Ca(2+) influx via the L-type channels, connected to memory mechanisms, and
through Src/ERK/cyclic AMP response element-binding protein activation in single hippocam-
pal neurons [88]. The presence of the L-type Ca (2+) channel inhibitor, nifedipine (10 microM),
partially inhibits 17 β E2 [89].
It was discovered an aging decrease of about 50% of ER-α-labeled synapses [37, 45], with
alteration in the ratio of ER-β to ER-α, fact that contributes to age-related decreases in the
capacity to form additional spines and synapses in response to E2 in rats. In addition,
synaptic pAkt thought is activated by ER-α [90], which is also decreased dramatically in
aged CA1 axospinous synapses [91], as is ER-β [92], suggesting that several key players in
the local synaptic response to E2 are compromised with age in female rats.
It was reported for the first time in Mont Sinai University (New-York, USA) [93] that in the
monkey’s neocortex 46, approximately 50% of the axospinous synapses contains ER-α, with
axon terminals more likely to have ER-α than spines, and that presynaptic ER-α was often
associated with vesicles, whereas postsynaptic ER-α was widely distributed in the PSD, adja-
cent to the PSD, and in the spine core.
The duration of brain’s estrogen deprivation is connected to C terminus of heat shock cognate
protein (Hsc) 70-interacting protein (CHIP)-mediated proteasomal degradation of hippocampal
Sex Hormones in Neurodegenerative Processes and Diseases284
estrogen receptor-α in conditions of rats’ global ischemia, or of aging hippocampal CA1 region
[9]. Natural aging is associated with increased ER-α and ER-β CHIP binding and ubiquitination,
and with decreased ER-α and ER-β levels in the hippocampal CA1 region, fact that is different
from the aging uterus in the rat model of long-term E2 deprivation (LTED) or after ovariectomy,
where the level of ER via the ubiquitin-proteasome degradation pathway is increasing after
estrogen exposure [9].
The studies on rats and monkeys [39] from Mount Sinai School of Medicine (New York, USA)
have emerged three key findings: (1) synaptic ER-α is present in axospinous synapses in
monkeys dorsolateral prefrontal cortex, in area 46; (2) it is stable across treatment and age
groups (which is not the case in rat hippocampus); and (3) the abundance and distribution of
synaptic ER-α is a key correlate of individual variation in cognitive performance in certain age
and treatment groups.
Another interesting and important findings about rats cortex are that ER-α can modulate
synaptic function and behavior even in the absence of circulating gonadal E2, in response to
E2 synthesized within neurons [94], and that ER-α may initiates the non-genomic signaling
mechanisms modulating synaptic plasticity in the hippocampus in response to either circulat-
ing or locally synthesized E2 [39, 93]. These findings are considered of great importance for the
design of HT strategies for both surgically and naturally menopausal women.
The detected levels of ERs in postmortem brain tissue of AD patients is related to the severity
of cognitive impairment assessed proximate to death, and only the reduction of ER-α from
frontal cortex is correlated to Mini-Mental State Examination score, not the ER-β [95]. The
spectrometry, immunohistochemistry, and quantitative real-time PCR of the autopsied Japa-
nese AD patients compared to controls [96] have revealed a glial nuclear ER-β expression
significantly lower in white matter in the AD group vs. controls, without any significant
differences in estrogen concentrations, and the conclusion was that estrogens have effects on
glias and neurons in the etiology of AD, and the correlation between BMI and estrogen
concentrations in the frontal lobe suggests the importance of non-brain sources of estrogens
particularly in controls.
Long-term E2 treatment initiated 14 days prior to global ischemia in ovariectomized female
rats demonstrated that E2 at near physiological concentrations acts via the IGF-1 receptor to
protect the functional integrity of hippocampal CA1 neurons and synapses in conditions of
global ischemia, but not the classical ER-α or β. [97]. The transactivation of IGF-1 receptors and
stimulation of ERK/MAPK signaling pathway maintains CREB activity in the ischemic CA1.
All three types of ERs cooperate in neuroprotection against AD [98], in association to intracel-
lular calcium signaling cascade, which is very important, and the ER-α is the central key, for
maintaining channel inactivation and may be relevant in neuronal preservation against Aβ
injury. It was demonstrated that combination of ERm and caveolin in caveolae, and ER-α-
mediated inhibition of Death domain-associated protein translocation may protect neurons
against Aβ injury. ER-α and IGF-IR co-activation may mediate neuroprotection, and many
other growth factors and intracellular signaling responses triggered by ER-α may play impor-
tant roles in the process [98].These data are crucial for contemporary societies, with high risks
for diabetes mellitus, in all populations. A very recent study from the University of Missouri,
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St. Louis (USA) [99] demonstrated the neuroprotection of the coupling of IGF1 to estrogens
and/androgens. It is considered that both steroids are involved in many neuroprotective
processes that operate on similar signaling cascades [100].
Another tested hypothesis is upon GPR30 that act together with intracellular estrogen recep-
tors to activate cell signaling pathways to promote hippocampal neuron survival after global
ischemia [101]. E2 at physiological concentrations intervenes in apoptotic death cascades and
ameliorates neuronal death, increasing BCL-2 expression in rat hippocampal neurons [88] (in
experimental models of focal and global ischemia), but the proper mechanism is still unclear.
Regarding ERs, there are new details about the genes, and mRNA variants of ER-α expressed
in different parts of the human brain, and there are specific ER-α mRNA splice variants or
isoforms of ER-α in the medial mammillary nucleus (MMN) in AD [102] or in the frontal cortex
in AD patients [95], and their relationship to cognitive impairment.
There are some therapeutic indications for cognition and memory support, which are par-
tially controversial. The first is regarding the benefits from the upregulation of the expression
of ER-α, but not of ER-β, in the hippocampus of aged animals, in order to restore the potential
of E2 treatments and rejuvenate E2-induced hippocampal plasticity [78]. The second are from
the results of a multinational study [103] sustaining the beneficial effects of long-term treat-
ment with diarylpropionitrile (DPN, 0.05 mg/kg/day, sc.), a selective ER-β agonist, on the
hippocampal transcriptome in ovariectomized, middle-aged (13 months) rats. The results
reveal the contribution of ER-β-mediated processes to the regulation of transcription, transla-
tion, neurogenesis, neuromodulation, and neuroprotection in the hippocampal formation,
and the authors concluded that the findings are supporting the notion that selective activation
of ER-β may be a viable approach for treating the neural symptoms of E2 deficiency in
menopause. There are studies suggesting that DPN—a selective ER-β agonist—mimics many
basic effects of E2 in the hippocampus and enhance mice’s hippocampus-dependent spatial
memory [104, 105].
Recent studies are involving the genetic polymorphism of ERs, especially of ER-β in cognitive
impairment and increased risk for AD predominantly in women [106]. It was examined that
the role of single nucleotide polymorphisms (SNP) in the ERs genes: rs9340799, rs2234693,
rs2228480 (in the ESR1 gene), and rs4986938 (in the ESR2 gene) as a risk factor for amnesic
mild cognitive impairment (MCI) and AD. The less represented alleles of SNPs studied are
associated with MCI and AD in women APOEε4 allele carriers [107, 108]. Some studies are
focusing the association of Eε4 allele of apolipoprotein E gene to obesity, inflammation, and
the risk of AD. Although, the pathways underlying this relationship are unclear the sex steroid
hormones may be the connection [109, 110].
The epigenetic processes are associated to brain aging. The post-translational histone changes and
DNAmethylation are modulating the hippocampal memory-enhancing effects of E2 [111, 112].
3.2. Progesterone receptors
P4 has neuroprotective effects mediated by various mechanisms P4 or its metabolites-
regulated neural responses are mediated by an array of progesterone receptors (PRs) which
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are broadly expressed throughout the brain, inclusive the hippocampus, and can be detected
in every neural cell type [113]. There are known the classic nuclear PR-A (the N-terminally
truncated form of PR-B) and PR-B receptors, and splice variants of each, explaining the P4
genomic mechanism of action through specific progesterone response elements (PRE) within
the promoter region of target genes to regulate transcription of the genes [114], and the two
types of cell surface-associated proteins [membrane PRs (mPRs) and the progesterone mem-
brane receptor component (PGMRC)].These PRs induce classic regulation of gene expression
while also transducing signaling cascades that originate at the cell membrane and ultimately
activate transcription factors. As for estrogens the genomic and non-genomic mechanisms of
P4 are coupled, so the distinctions are not as clear-cut as was first thought [115]. The nuclear
PRs are up-regulated by E2 in glial and neural cells, but more in the glial cells, implicating
crucial progenitor cells, as preferential targets of P4 [116] (Figures 1 and 2).
Figure 1. Progesterone nuclear receptor (pgr) is upregulated by estrogen. Experiments on developing and adult brain of
zebrafish, and larvae. Legend: Fold induction of P4 expression after treatment of adult zebrafish with an aromatase
inhibitor (A, 106 M of ATD) or estradiol (B, 107 M of 17β-estradiol), and larvae with E2 (C, 108 M of 17β-estradiol).
The graphs present the mean value +/ the standard deviation. Asterisk (*) indicates significant differences (p < 0.05,
Student’s t test). Panel A: the aromatase inhibitor (ATD) leads to a significant decrease of pgr expression in individual
brains of adult zebrafish (n = 4). Panel B, the estrogenic treatment leads to a significant increase of pgr expression in pools
of 5 brains of adult zebrafish (n = 3). Panel C: the estrogenic treatment leads to a significant increase of pgr expression in
pool of 20 larvae (n = 2).
New Insights for Hormone Therapy in Perimenopausal Women Neuroprotection
http://dx.doi.org/10.5772/intechopen.74332
287
PR-A is exerting a negative control on PR-B-mediated transcription, and the mediated transcrip-
tion of the ER and glucocorticoid receptors [117], fact that may underlie, at least in part, the
mechanism by which progesterone functionally antagonize the effects of estrogen. PRA and PRB
can interact as dimers with DNA progesterone responsive element, and with signaling proteins
of the Src/Ras/Erk pathway outside the nucleus [118]. The “non-genomic” mechanisms explains
the non-reproductive P4 actions, the rapid activation of cytoplasmic kinase signaling that can
result in both transcription-independent and transcription-dependent effects. These “non-
genomic” actions can be partially explained by membrane transport via nuclear receptor [119].
The mPRs (molecular mass of approximately 40 kDa) had thought to be comprised of three
subtypes, mPR α, β, and γ, which belong to the seven-transmembrane domain adiponectin Q
receptor (PAQR) family, plus two newly discovered subtypes (mPRδ, and mPRε) [120]. It was
shown that cDNAs for the mPRα subtypes of spotted seatrout (st-mPRalpha) and humans (hu-
mPRα-) encode progesterone/progestin receptors that display many functional characteristics of
G protein-coupled receptors [121], and that mPRβ promotes progesterone-dependent neurite
Figure 2. Experiments on Zebrafish hypothalamicP4 receptors. Legend: Analysis of the P4 staining intensity in the ventral
subpallium and in the anterior hypothalamus revealing a stronger intensity (mean value +/ the standard deviation).in
the radial cells than neural cells (p < 0.001 Student’s t test). Figures 1 and 2 are adapted from [116].
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outgrowth in PC12 neuronal cells via non-G protein-coupled receptor (GPCR) signaling [122].
Progesterone receptor membrane component-1 (PGRMC-1) and PGRMC-2, with a single-
transmembrane domain protein, are mediating the rapid non-genomic effects of E2 and P4, such
as the activation of MAPK signaling and intracellular Ca2+ increase [123, 124] mPRβ activates
also MAPK cascade, without GPCR signaling, and progesterone-stimulatedmPRβ activation did
not exhibit the elevation of [Ca2+] [121]. In comparison to the mPRs, the single-transmembrane
protein Pgrmc1 (molecular mass 25–28 kDa) and the related Pgrmc2 are a part of a multi-protein
complex that binds to P4, other steroids, and to pharmaceutical compounds [123]. Besides the
location to membrane surface, Pgrmc1 was reported to have subcellular localization: in endo-
plasmic reticulum, Golgi apparatus, and nuclei [125].
PRs are differentially expressed in neurons, in oligodendrocytes, astrocytes, and reactive
microglia, the mPRα expression is observed in oligodendrocytes, astrocytes, and reactive
microglia. The increase in mPR expression was proposed to mediate the anti-inflammatory
effects of progesterone under conditions of injury [126].
The classical PR and mPRs have overlapping regional expression (e.g., both are expressed in
the hippocampus, cortex, hypothalamus, and cerebellum), but their profile of ligand specificity
is not identical [126]. The “non-classical/non-genomic” effects of P4 can be initiated rapidly at
the cell surface to activate intracellular signaling pathways, through modulation of putative
cell surface receptors, ion channels, and cytoplasmic second messenger cascades, the rapid
activation of cytoplasmic kinase signaling can result in both transcription-independent and
transcription-dependent effects.
Among the rapid non-genomic signaling pathways activated by P4 are the extracellular signal-
related kinase (ERK) pathways [127], cAMP/protein kinase A (PKA) signaling [128], PKG
signaling [129], Ca2+ influx/PKC activation [130], phosphatidylinositol 3-kinases (PI3 K)/Akt
pathway [124], and other signal transduction cascades. P4 or its metabolites can act directly
and rapidly on neurotransmitter receptors as the GABA-A receptor [131] and Sigma-1/2 recep-
tors [132] to regulate cellular function.
The consequences of activation of these signaling pathways are numerous and include influ-
ences on neurotrophin release [125], neural progenitor proliferation, regulation of intracellular
Ca2+ levels, and regulation of cell viability [57, 127, 131] all of which can contribute to the
overall health and function of the brain.
3.3. Androgens mechanisms in neuroprotection
Androgen neuroprotective effects are mediated both directly by activation of androgen recep-
tors (ARs) pathways, and indirectly by aromatization to estradiol and initiation of protective
estrogen signaling mechanisms, but this last action is not totally accepted [133–135]. The
knowledge on the effects of testosterone on women cognitive capacities are few.
Testosterone protects primary human neurons against serum deprivation [134], cultured rat hip-
pocampal neurons against extracellular Aβ toxicity [136], rat neurons against heat shock-mediated
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hyperphosphorylation of tau by modulating glycogen synthase kinase 3 activation [85], cerebellar
granule neurons against oxidative stress [133], and rat hippocampal neurons against kainic acid-
induced toxicity [135] transiently activate mitogen-activated protein kinase (MAPK) in cultured
hippocampal neurons, as evidenced by phosphorylation of extracellular signal-regulated kinase
(ERK)-1 and ERK-2 and by this effect subsequently drives neuroprotection [137].
4. Perspectives
Brain aging and neurodegenerative diseases have a multifactorial nature, metabolic and inflam-
matory changes from the moment of transition to menopause, blood-brain barrier disruption, and
aberrant microglial activation can be modulated or prevented in a moment prior to their onset in
the “critical period of opportunity,” if the clinicians and the patients are both interested and have a
good understanding of very early perimenopausal symptoms. The differences between estrogen
types, between progesterone and progestins, between the classes of steroid receptors agonists—
NeuroSERMs (novel neuro-selective estrogen receptor modulator) and PhytoSERMs (phyto-
selective estrogen receptor modulator), and the new molecules tested in high-tech laboratories,
will help the clinicians to recommend the best neurotrophic, neuroprotective molecule without
any breast or uterine harmful action.
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